Adezmapimod (SB 203580) 是一种选择性的,ATP 竞争性的p38 MAPK抑制剂,对SAPK2a/p38和SAPK2b/p38β2的IC50分别为 50 nM 和 500 nM。Adezmapimod 抑制 LCK,GSK3β 和 PKBα,IC50比 SAPK2a/p38 高 100-500 倍。Adezmapimod 不抑制 JNK 活性,是一种自噬 (autophagy) 和线粒体自噬 (mitophagy) 激活剂。
生物活性 | Adezmapimod (SB 203580) is a selective and ATP-competitivep38 MAPKinhibitor withIC50s of 50 nM and 500 nM forSAPK2a/p38andSAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disruptJNKactivity and is anautophagyandmitophagyactivator[1]. |
IC50& Target[1] | p38 50 nM (IC50) | p38β2 500 nM (IC50) |
|
体外研究 (In Vitro) | Adezmapimod (SB 203580) (preincubated with 0-30 μM for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2) prevents the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50of 3-5 μM[1]. SB203580 blocks PKB phosphorylation (IC503-5 μM). SB203580 inhibitsthe phosphorylation of Ser473 in a dose-dependent manner in both CT6 and activated human T cells and IL-2-responsive BA/F3 F7 B cells[1].
Cell Proliferation Assay[1] Cell Line: | CT6, BA/F3 cell line F7, and PBMC/T cells | Concentration: | 0-30 μM | Incubation Time: | Preincubated with 0-30 μM SB203580 for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2 | Result: | Prevented the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50of 3-5 μM. |
Western Blot Analysis[1] Cell Line: | CT6 cells, activated human T cells, and BA/F3 F7 cells | Concentration: | 0-30 μM | Incubation Time: | Preincubated with 0-30 μM SB203580 for 1 h before stimulating with 20 ng/mL IL-2 for 5 min | Result: | Inhibited the phosphorylation of PKB at Ser473 in a dose-dependent manner. |
|
体内研究 (In Vivo) | Adezmapimod (SB 203580) (5 mg/kg/day; intra peritoneal injected daily for 16 consecutive days, in female atymic Nu/Nu mice) treatment, p38WT tumors show a significantly smaller tumor burden when compared with p38TM tumors that were treated in parallel[1].
Animal Model: | Six-week-old female atymic Nu/Nu mice CAL27 p38WT and p38TM tumors[1] | Dosage: | 5 mg/kg/day | Administration: | Intra peritoneal injected daily for 16 consecutive days | Result: | After 2 weeks treatment, CAL27 p38WT tumors were significantly smaller; CAL27 p38TM tumors were not affected by the p38 inhibitor (n=10). |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 20 mg/mL(52.99 mM;ultrasonic and warming and heat to 60℃) 配制储备液 1 mM | 2.6495 mL | 13.2475 mL | 26.4950 mL | 5 mM | 0.5299 mL | 2.6495 mL | 5.2990 mL | 10 mM | 0.2649 mL | 1.3247 mL | 2.6495 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 0.5%CMC-Na/saline water Solubility: 16.67 mg/mL (44.17 mM); Suspended solution; Need ultrasonic 2. 请依序添加每种溶剂: 5% DMSO 40%PEG300 5%Tween-80 50% saline Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution 3. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2 mg/mL (5.30 mM); Clear solution; Need ultrasonic
此方案可获得 2 mg/mL (5.30 mM) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 4. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2 mg/mL (5.30 mM); Clear solution; Need ultrasonic
此方案可获得 2 mg/mL (5.30 mM) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 5. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: 2 mg/mL (5.30 mM); Clear solution; Need ultrasonic
此方案可获得 2 mg/mL (5.30 mM) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|